In non-small cell lung cancer (NSCLC), the combination of DSF with anti-PD-L1 effectively overcomes drug resistance and enhances antitumor effects by modulating hypoxia-inducible factor 1 (HIF-1) signaling (72). Here, CD274 is linked to non-small cell lung carcinoma.